At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab and Belzutifan for Clear Cell Renal Cell Carcinoma. Currently recruiting, targeting 10 participants across 1 site.
Detailed Summary
To learn if belzutifan alone, pembrolizumab alone, or belzutifan and pembrolizumab in combination given before a total or partial nephrectomy (surgery to remove all or part of a kidney) can help to control locally advanced ccRCC.
Study Details
Timeline
Arms & Interventions
Participants will undergo evaluations at baseline, 3 weeks, 6 weeks, 9 weeks, and 12 weeks after initiation of treatment
Participants will undergo evaluations at baseline, 3 weeks, 6 weeks, 9 weeks, and 12 weeks after initiation of treatment
Participants will undergo evaluations at baseline, 3 weeks, 6 weeks, 9 weeks, and 12 weeks after initiation of treatment
Interventions
Oral administration
Oral administration